These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 16059630

  • 1. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application.
    Niikura K, Takeshita N, Takano M.
    J Bone Miner Res; 2005 Sep; 20(9):1579-88. PubMed ID: 16059630
    [Abstract] [Full Text] [Related]

  • 2. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase.
    Niikura K, Takano M, Sawada M.
    Br J Pharmacol; 2004 Jun; 142(3):558-66. PubMed ID: 15148249
    [Abstract] [Full Text] [Related]

  • 3. FR177995, a novel vacuolar ATPase inhibitor, exerts not only an inhibitory effect on bone destruction but also anti-immunoinflammatory effects in adjuvant-induced arthritic rats.
    Niikura K, Nakajima S, Takano M, Yamazaki H.
    Bone; 2007 Apr; 40(4):888-94. PubMed ID: 17157574
    [Abstract] [Full Text] [Related]

  • 4. A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform.
    Nyman JK, Väänänen HK.
    Calcif Tissue Int; 2010 Sep; 87(3):273-83. PubMed ID: 20596699
    [Abstract] [Full Text] [Related]

  • 5. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase.
    David P, Nguyen H, Barbier A, Baron R.
    J Bone Miner Res; 1996 Oct; 11(10):1498-507. PubMed ID: 8889850
    [Abstract] [Full Text] [Related]

  • 6. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
    Nijenhuis T, van der Eerden BC, Hoenderop JG, Weinans H, van Leeuwen JP, Bindels RJ.
    J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of bone resorption in vitro by antisense RNA and DNA molecules targeted against carbonic anhydrase II or two subunits of vacuolar H(+)-ATPase.
    Laitala T, Väänänen HK.
    J Clin Invest; 1994 Jun; 93(6):2311-8. PubMed ID: 8200964
    [Abstract] [Full Text] [Related]

  • 8. Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis.
    Niikura K.
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):555-62. PubMed ID: 17187252
    [Abstract] [Full Text] [Related]

  • 9. Vacuolar ATPase as a drug discovery target.
    Niikura K.
    Drug News Perspect; 2006 Apr; 19(3):139-44. PubMed ID: 16804565
    [Abstract] [Full Text] [Related]

  • 10. Comparative analysis of the effects of a novel vacuolar adenosine 5'-triphosphatase inhibitor, FR202126, and doxycycline on bone loss caused by experimental periodontitis in rats.
    Niikura K.
    J Periodontol; 2006 Jul; 77(7):1211-6. PubMed ID: 16805684
    [Abstract] [Full Text] [Related]

  • 11. A novel synthetic triazolotriazepine derivative JTT-606 inhibits bone resorption by down-regulation of action and production of bone resorptive factors.
    Chikazu D, Shindo M, Iwasaka T, Katagiri M, Manabe N, Takato T, Nakamura K, Kawaguchi H.
    J Bone Miner Res; 2000 Apr; 15(4):674-82. PubMed ID: 10780859
    [Abstract] [Full Text] [Related]

  • 12. The a3 isoform vacuolar type H⁺-ATPase promotes distant metastasis in the mouse B16 melanoma cells.
    Nishisho T, Hata K, Nakanishi M, Morita Y, Sun-Wada GH, Wada Y, Yasui N, Yoneda T.
    Mol Cancer Res; 2011 Jul; 9(7):845-55. PubMed ID: 21669964
    [Abstract] [Full Text] [Related]

  • 13. Effects of wortmannin analogs on bone in vitro and in vivo.
    Sato M, Bryant HU, Dodge JA, Davis H, Matter WF, Vlahos CJ.
    J Pharmacol Exp Ther; 1996 Apr; 277(1):543-50. PubMed ID: 8613966
    [Abstract] [Full Text] [Related]

  • 14. Electrophysiological characterization of ATPases in native synaptic vesicles and synaptic plasma membranes.
    Obrdlik P, Diekert K, Watzke N, Keipert C, Pehl U, Brosch C, Boehm N, Bick I, Ruitenberg M, Volknandt W, Kelety B.
    Biochem J; 2010 Mar 15; 427(1):151-9. PubMed ID: 20100168
    [Abstract] [Full Text] [Related]

  • 15. Ion transporters involved in acidification of the resorption lacuna in osteoclasts.
    Henriksen K, Sørensen MG, Jensen VK, Dziegiel MH, Nosjean O, Karsdal MA.
    Calcif Tissue Int; 2008 Sep 15; 83(3):230-42. PubMed ID: 18787885
    [Abstract] [Full Text] [Related]

  • 16. V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.
    Qin A, Cheng TS, Pavlos NJ, Lin Z, Dai KR, Zheng MH.
    Int J Biochem Cell Biol; 2012 Sep 15; 44(9):1422-35. PubMed ID: 22652318
    [Abstract] [Full Text] [Related]

  • 17. Characterization and cellular distribution of the osteoclast ruffled membrane vacuolar H+-ATPase B-subunit using isoform-specific antibodies.
    Mattsson JP, Skyman C, Palokangas H, Väänänen KH, Keeling DJ.
    J Bone Miner Res; 1997 May 15; 12(5):753-60. PubMed ID: 9144341
    [Abstract] [Full Text] [Related]

  • 18. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H, Susa M.
    Bone; 2004 Nov 15; 35(5):1144-56. PubMed ID: 15542040
    [Abstract] [Full Text] [Related]

  • 19. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption.
    Sørensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA.
    J Bone Miner Res; 2007 Oct 15; 22(10):1640-8. PubMed ID: 17576165
    [Abstract] [Full Text] [Related]

  • 20. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
    Hornby SB, Evans GP, Hornby SL, Pataki A, Glatt M, Green JR.
    Calcif Tissue Int; 2003 Apr 15; 72(4):519-27. PubMed ID: 12574877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.